AtaiBeckley Inc (ATAI)

• Market cap: $1.48B
• 1 day: 0.5%
• 5 days: -1.95%
• 1 month: 7.18%
• 3 months: 2.28%
• 6 months: -7.36%
• Year to date: 4.13%
• 1 year: 187.86%
• 5 years: -79.28%
• 10 years: -79.28%
• Sector: Healthcare
• Industry: Biotechnology

About: AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Employees: 99